The landmark FDA approval of the first MASH therapeutic, the orphan drug designation for systemic sclerosis trials, and the rapid advancement of IPF treatments through clinical phases have ignited
Ensuring equitable access to medicines is a cornerstone of the commitments many pharmaceutical companies make to their customers, patients, and stakeholders – but, recently, there has been